Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA-1: Ambrisentan Add-on in PAH
NCT00617305Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2008
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Started Apr 2008; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00617305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617305.